Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease
Author:
Publisher
Oxford University Press (OUP)
Subject
Gastroenterology,Immunology and Allergy
Reference50 articles.
1. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
2. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
3. Review article: infliximab therapy for inflammatory bowel disease - seven years on
4. Optimizing anti-TNF treatment in inflammatory bowel disease
Cited by 112 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases;Middle East Journal of Digestive Diseases;2023-04-30
2. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease;Pediatric Inflammatory Bowel Disease;2023
3. A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease;Journal of Crohn's and Colitis;2022-10-27
4. Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review;American Journal of Ophthalmology Case Reports;2022-09
5. The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease;Gastroenterology & Hepatology: Open Access;2022-03-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3